SOURCE: Kantrowitz, Goldhamer & Graifman, P.C.

November 17, 2014 16:45 ET

Notice of Filing of Securities Fraud Class Action Against Aeterna Zentaris Inc. by Kantrowitz, Goldhamer & Graifman, P.C.

CHESTNUT RIDGE, NY--(Marketwired - Nov 17, 2014) - Kantrowitz, Goldhamer & Graifman, P.C. has filed a securities fraud class action against Aeterna Zentaris Inc. ("Aeterna Zentaris" or the "Company") (NASDAQ: AEZS) and certain of its senior executives in the United States District Court for the District of New Jersey (the "Court").

On November 6, 2014, Aeterna Zentaris announced that the FDA had issued a Complete Response Letter ("CRL") refusing to approve the Company's New Drug Application referencing "the lack of complete and verifiable source data for determining whether patients were accurately diagnosed with AGHD." The case alleges materially false or misleading statements made by defendants with respect to the safety and efficacy of the Company's drug Macrilen.

The lawsuit is brought on behalf of a class (the "Class") of investors who purchased shares of Aeterna Zentaris between and including June 26, 2012 and November 5, 2014 (the "Class Period"). If you are a member of the Class and wish to serve as a lead plaintiff, then you must move the Court no later than January 12, 2015. However, as a member of the Class, you are under no obligation to move to be appointed lead plaintiff.

If you would like to discuss this investigation, or if you have any questions concerning your rights as a potential lead plaintiff, you may contact: Gary S. Graifman, Esq. of Kantrowitz, Goldhamer & Graifman, P.C. toll free at (800) 660-7843, or via e-mail at

Kantrowitz, Goldhamer & Graifman, P.C., based in New York and Montvale, New Jersey, has extensive experience in shareholder and securities class action cases, and the firm has recovered millions of dollars for defrauded investors.

Attorney Advertising. Prior Results Do Not Guarantee A Similar Outcome.

Contact Information

  • Contact:

    Gary S. Graifman, Esq.
    210 Summit Avenue
    Montvale, New Jersey
    Telephone: (800) 660-7843